Literature DB >> 31753520

Evaluation of the automated BD Phoenix CPO Detect test for detection and classification of carbapenemases in Gram negatives.

Imane Saad Albichr1, Ahalieyah Anantharajah1, Magali Dodémont2, Marie Hallin2, Alexia Verroken1, Hector Rodriguez-Villalobos3.   

Abstract

We evaluated the performance of the automated BD Phoenix CPO Detect test (BD-CPO test) for detection and Ambler classification of carbapenemases in Enterobacteriaceae, P.aeruginosa and A.baumannii complex. A collection of 287 Gram-negative clinical isolates, with a reduced susceptibility to at least one carbapenem including 184 carbapenemase-producing organisms (CPO) and 103 non-CPO, was tested. The BD-CPO test showed an overall sensitivity of 89.7% and specificity of 83.5% for carbapenemase detection. 1/7 of class A, 82.9% of class B, and 89.8% of class D carbapenemases were correctly classified. Poor detection sensitivity of 68.9% and specificity of 62.1% in P.aeruginosa was observed. However, combination with ceftazidime/avibactam susceptibility, provided by this panel, increased the performances for P.aeruginosa. The integration of an automated carbapenemase detection and classification in routine susceptibility panels would save time and help for therapeutic management. Further developments are needed to improve the accuracy of the BD-CPO test.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ambler classification; BD CPO detect test; Carbapenemase detection; Carbapenemase producing organism; Gram-negative; Phoenix

Mesh:

Substances:

Year:  2019        PMID: 31753520     DOI: 10.1016/j.diagmicrobio.2019.114911

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  2 in total

1.  Multicenter Evaluation of Ceftazidime-Avibactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa on the Vitek 2 System.

Authors:  Romney Humphries; Shelley Campeau; Thomas E Davis; Kristin J Nagaro; Vincent J LaBombardi; Simone Franklin; Lisa Heimbach; Hari P Dwivedi
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

2.  Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales.

Authors:  Jingjia Zhang; Peiyao Jia; Ying Zhu; Ge Zhang; Yingchun Xu; Qiwen Yang
Journal:  Front Med (Lausanne)       Date:  2021-04-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.